HC Wainwright & Co. Reiterates Buy on Kinnate Biopharma, Maintains $24 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Kinnate Biopharma (NASDAQ:KNTE) and maintained a $24 price target.
June 08, 2023 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns reiterates a Buy rating on Kinnate Biopharma and maintains a $24 price target.
The reiterated Buy rating and maintained $24 price target by HC Wainwright & Co. analyst Robert Burns indicates a positive outlook for Kinnate Biopharma. This news is likely to have a positive short-term impact on the stock price as it shows confidence in the company's potential and valuation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100